Aarti Drugs

Market Cap: Small Cap
Industry: Pharmaceuticals & Biotechnology
ISIN: INE767A01016
NSEID: AARTIDRUGS
BSEID: 524348

INR

405.00

-2.85 (-0.7%)

BSENSE

Dec 05

BSE+NSE Vol: 1.58 lacs

Click here to access the older version

Company CV

About Aarti Drugs Ltd

Aarti Drugs Ltd

Small Cap

Pharmaceuticals & Biotechnology

Aarti Drugs Limited (ADL), incorporated in September, 1984 is a prominent manufacturer of APIs, Pharma Intermediates, and Specialty Chemicals. The Company operates as part of the Aarti Group, a conglomerate with a net worth of USD 900 million. With over 50 compounds for Antibiotics, Anti Protozoal, Anti-Inflammatory, Anti-diabetic, Anti Fungal and Cardioprotectant therapeutic segments, the Company has emerged as market leader in APIs.

Company Coordinates

Company Details

Plot No N-198 MIDC Tarapur, Pamtembhi Village Palghar Tal Thane Maharashtra : 401506

Tel: 91-22-24072249

http://www.aartidrugs.com

investorrelations@aartidrugs.com

Registrar Details

Link Intime India Pvt Ltd, C-13 Pannalal Silk Compound, L B S Marg, Bhandup , Mumbai

Capital Structure

Present Equity Capital

INR 92.60 Cr

Number of Shares

9.26 Cr

Face Value

INR 10.0

Date

Number
of Shares(Cr)

Equity
Capital (Rs Cr)

Shares Added

Face Value (Rs)

Reason

20-May-2021

9.26

92.60

-600000

Buy Back of Shares

30-Sep-2020

9.32

93.20

69900000

Bonus Issue

16-Dec-2016

2.39

23.86

-360000

Buy Back of Shares

24-Mar-2015

2.42

24.22

12108550

Bonus

24-Mar-2015

2.42

24.22

12108550

Bonus

20-Dec-2009

1.21

12.11

400000

Conversion of Warrants

20-Dec-2009

1.21

12.11

400000

Conversion of Warrants

Shareholding

Shareholding Snapshot

Shareholding Compare (%holding)

Majority shareholders

Promoters

Pledged Promoter Holdings

None

Mutual Funds

Held by 7 Schemes (9.81%)

FIIs

Held by 71 FIIs (2.69%)

Promoter with highest holding

Prakash Moreshwar Patil (9.32%)

Highest Public shareholder

Dsp Small Cap Fund (8.01%)

Individual Investors Holdings

23.58%

Board of Directors

Period

Management

Designation

Remuneration

Prakash M Patil

CMD & Executive Director

2.76 cr

Rashesh C Gogri

ED / MD / Promoter

2.56 cr

Harshit M Savla

ED / Joint MD / Promoter

2.56 cr

Harit P Shah

E D & Wholetime Director

2.56 cr

Uday M Patil

WTD & Executive Director

31.93 lacs

Narendra Jagannath Salvi

Non Executive Director

1.2 lacs

Navin Chapshi Shah

Independent Non Exe. Director

2.7 lacs

Krishnacharya G Akamanchi

Independent Non Exe. Director

2.5 lacs

Priti Savla

Independent Non Exe. Director

2.3 lacs

Ankit Vikram Paleja

Independent Non Exe. Director

1.9 lacs

Bhaskar Narayan Thorat

Independent Non Exe. Director

1.1 lacs

Neha Gada

Independent Non Exe. Director

1.1 lacs

Raw Materials

Raw Materials Dashboard

Raw Materials

Amount(Rs Cr)

% of RM Cost

Purchase of Trading goods

40.5261

Purchase of Trading goods

Finished Goods

Finished Goods Dashboard

Finished Goods

Amount(Rs Cr)

% of Sales Turnover

Pharmaceutical

1,454.25

100.00%

Pharmaceutical

Stock DNA

Revenue and Profits:

Net Sales:

653 Cr

(Quarterly Results - Sep 2025)

Net Profit:

45 Cr

Industry

Pharmaceuticals & Biotechnology

Market cap

INR 3,706 Cr (Small Cap)

P/E

19.00

Industry P/E

Dividend Yield

0.25%

Debt Equity

0.38

Return on Equity

13.56%

Price to Book

2.54